Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Larson, R.
Right arrow Articles by Dillon, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Larson, R.
Right arrow Articles by Dillon, H.
American Journal of Health-System Pharmacy, Vol 59, Issue 3, 270-277
Copyright © 2002 by American Society of Health-System Pharmacists


Articles

Monitoring method for surface contamination caused by selected antineoplastic agents

RR Larson, MB Khazaeli, and HK Dillon


A method of evaluating surface contamination caused by selected antineoplastic agents was studied. The antineoplastic agents tested were cyclophosphamide, ifosfamide, doxorubicin hydrochloride, fluorouracil, and paclitaxel. Each agent was reconstituted and prepared as a stock solution. A 0.1-mL portion of each solution was spread evenly over a 600-cm2 area of a stainless steel surface, a resin countertop surface, and a vinyl flooring surface. After drying, the surfaces were wiped with each of two types of commercially available wiping materials (What-man no. 42 filters and Kimberly-Clark Kimwipes). A blend of methanol, acetonitrile, and buffered water was used both as the wetting agent for wiping the surfaces and as a desorbing solution. The desorbate was analyzed for drug concentration by reverse-phase high-performance liquid chromatography (HPLC). Mean +/- S.D. percent total recovery ranged from 72.4% +/- 17.6% to 95.3% +/- 2.9% for the vinyl surface wiped with filters, 91.5% +/- 5.4% to 104.7% +/- 0.8% for the resin surface wiped with filters, 73.9% +/- 2.3% to 95.3% +/- 1.7% for the stainless steel surface wiped with filters, and 18.2% +/- 1.4% to 372.8% +/- 8.0% for the stainless steel surface wiped with Kimwipes. Results were best for ifosfamide and cyclophosphamide. Kimwipes were deemed ineffective for this monitoring method because an ingredient interfered with the quantitative analytical tests. A wipe-sampling, desorption, and HPLC method for monitoring surface contamination by selected antineoplastic agents was sufficiently accurate and sensitive to evaluate surfaces typically found in both the pharmacy and drug administration areas of oncology treatment facilities.
 



This article has been cited by other articles:


Home page
ANN OCCUP HYGHome page
K. Touzin, J.-F. Bussieres, E. Langlois, M. Lefebvre, and C. Gallant
Cyclophosphamide Contamination Observed on the External Surfaces of Drug Vials and the Efficacy of Cleaning on Vial Contamination
Ann. Hyg., November 1, 2008; 52(8): 765 - 771.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
B. R. Harrison, B. G. Peters, and M. R. Bing
Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques.
Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1736 - 1744.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
T. H. Connor, P. J. M. Sessink, B. R. Harrison, J. R. Pretty, B. G. Peters, R. M. Alfaro, A. Bilos, G. Beckmann, M. R. Bing, L. M. Anderson, et al.
Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies
Am. J. Health Syst. Pharm., March 1, 2005; 62(5): 475 - 484.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society of Health-System Pharmacists.